http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2633032-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5d65415aec835afce8c9d26ad725006 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4155 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4155 |
| filingDate | 2016-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6dd41d392b18f92a48a97bcd6267d9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73512b3956e1341595aea4f3477f7d09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfcb3c03ae0e35f9bda36fd82270ddb5 |
| publicationDate | 2017-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2633032-C1 |
| titleOfInvention | New inhibitors of serine-threonine kinases, including for treatment of oncological diseases and tuberculosis |
| abstract | FIELD: pharmacology. n SUBSTANCE: invention relates to compounds of the general formula n or n n=0-2; A is independently selected and is a 5-7-membered aromatic heterocycle containing 1-2 N atoms and 0-1 S atom; A contains 0-2 R substituents; R is independently selected and represents methyl or ethyl; B is independently selected and represents phenyl, 5-6-membered heteroaryl cycle containing 0-2 N atoms and 0-1 S atom, or 5-6-membered cycloalkyl containing 0-2 N atoms and 0-1 S atom; B contains 0-3 R 1 substituents; C is independently selected and represents phenyl, -NH 2 , -NH-C 1-3 -alkyl, -NH (C 1-3 -alkyl) C 1-3 -alkyl, a 5-6-membered heteroaryl cycle containing 0-2 N atoms and 0-1 S atom, or a 5-6-membered cycloalkyl containing 0-2 N atoms and 0-1 S atom; C contains 0-3 R 1 substituents; R 1 is independently selected and represents -C 1-6 -alkyl, halogen, phenyl, -C 5-7 -heteroaryl containing 1-2 N atoms and 0-1 S atom, -COOH, -CONH 2 , -NH 2 or -NHR 2 ; R 2 is independently selected and represents -C 1-6 -alkyl, -C (O) -C 1-8 -alkyl; the linker X is independently selected and is -CH 2 -, -C(=O)-CH 2 - or -CH 2 -O-group; the linker Q is independently selected and represents -NH- or -NH-C(O) -group; the Y linker is independently selected and represents -O-(CH 2 ) m or -C(O)-NH-(CH 2 ) m , where m=1-3; Z is independently selected and represents -CH 2 - group or an oxygen atom. n EFFECT: compounds are prospective for use in the therapy of diseases associated with the activity of serine-threonine kinases. n 13 cl, 2 tbl, 16 ex |
| priorityDate | 2016-05-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 327.